HMR insulin analog moving into Phase III; Hoechst takes $23.8 mil. charge for Seldane write-off.
Executive Summary
HOECHST MARION ROUSSEL INSULIN ANALOG HOE 901 TO BEGIN PHASE III trials in the U.S., Europe and Japan during 1997, the company announced April 29. The company described HOE 901 as "an innovative version of insulin with a long-lasting action." Lilly recently launched the insulin analog Humalog, which has a more rapid onset of glucose lowering activity and a shorter duration of action ("The Pink Sheet" June 24, 1996, p. 3).